# Abviro LLC

Canonical: https://abierto.us/vendors/abviro-llc-k3l6kxj9b6m7

- UEI: K3L6KXJ9B6M7
- CAGE: 75YF3
- Location: Bethesda, MD
- Awards in window: 2 (8 transactions), $9,318,257 obligated, February 14, 2024 to March 24, 2026

## Awarding agencies

- National Institutes of Health: 2 awards, $9,318,257

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $9,582,135
- 541711 Professional, Scientific, and Technical Services: -$263,878

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- 75N93023C00055 (definitive contract): $9,582,135, National Institutes of Health Niaid. To Conduct a Phase 2 Dengue Human Challenge Clinical Trial of Abviro Anti-Dengue Monoclonal Antibody (Mab) AV-1.. https://www.usaspending.gov/award/CONT_AWD_75N93023C00055_7529_-NONE-_-NONE-/
- HHSN272201600028C (definitive contract): -$263,878, National Institutes of Health Niaid. The Purpose of This Contract Is to Develop a Monoclonal Antibody (Mab) AV-1 as a Safe Injectable Therapeutic.. https://www.usaspending.gov/award/CONT_AWD_HHSN272201600028C_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/abviro-llc-k3l6kxj9b6m7.